The evolving RNA therapeutics landscape

The following article provides an in-depth analysis of the evolving landscape of CDMOs within the pharmaceutical industry. It draws insights from a comprehensive report by CPHI – entitled Global CDMO Trends: the 2024 outsourcing forecast – exploring dynamic shifts, emerging trends, and strategic partnerships that shape the global CDMO landscape.

LATEST VIDEO

Latest news

6th September 2024

CPHI Milan Announce Pharma Award finalists

5th September 2024

Lonza Completes Expansion of Microbial Manufacturing Facility in Visp (CH)

4th September 2024

HAYA Therapeutics Announces Collaboration with Lilly to Discover Genome Targets for Obesity Using RNA Platform

4th September 2024

OLON CONTINUES ITS GROWTH PATH AND ANNOUNCES A NEW ACQUISITION

4th September 2024

Tanvex Appoints Biopharma Industry Veteran Stephen Lam as CEO

3rd September 2024

Molport welcomes Diana Zelencova-Gopejenko as CEO

3rd September 2024

Enzene appoints new site Lead for Flagship US continuous bioManufacturing facility

13th August 2024

Syngene secures silver rating in EcoVadis sustainability index, ranking in top 15% of assessed companies

9th August 2024

Abzena Supplies Clinical Trial Material for Angiex’s Phase I Study of AGX101, a First-in-Class TM4SF1-directed ADC

8th August 2024

Pharma services boom in China as CPHI & PMEC China posts record attendance

30th July 2024

Piramal Pharma Solutions Achieves Revenue Threshold on Innovation Work

This week’s featured articles

Regulatory affairs is an all-female task at Cerbios-Pharma

Views from a round table at DCAT Week

Bringing success to antibody biologics development and manufacturing

People make the difference

An interview with BioVectra executives at CPHI Barcelona

Changing the game: The dynamics and complexities of switching delivery formats for sterile injectable therapies

Partnered with top industry events and organisations